You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

primary peritoneal

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

Recruiting
  • Mucinous Ovarian Cancer
  • +2 more
  • Bevacizumab + modified FOLFIRINOX
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 25, 2022

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Minneapolis, Minnesota
  • +1 more
Jan 27, 2023

Cancer, Solid Tumor, Ovarian Cancer Trial in Minneapolis (FT538, Enoblituzumab)

Not yet recruiting
  • Cancer
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Jan 24, 2023

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer Trial (Cisplatin, No treatment)

Not yet recruiting
  • Stage III Ovarian Cancer
  • +5 more
  • (no location specified)
Dec 12, 2022

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer Trial in New York (NY-ESO-1 peptide vaccine)

Completed
Has Results
  • Fallopian Tube Cancer
  • +2 more
  • NY-ESO-1 peptide vaccine
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 13, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +2 more
  • NY-ESO-1 OLP4
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Houston, Texas
  • +4 more
Oct 20, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Odense, Denmark
  • +3 more
Oct 16, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate

Recruiting
  • Ovarian Cancer
  • +2 more
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
Sep 12, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston (Chemotherapy, Olaparib, Therapeutic

Recruiting
  • BRCA-Mutated Ovarian Carcinoma
  • +30 more
  • Houston, Texas
    M D Anderson Cancer Center
May 27, 2022

Total Management of Ovarian Cancer

Not yet recruiting
  • Tumor of Female Reproductive System
  • Ovarian Cancer
  • No intervention
  • (no location specified)
Aug 30, 2023

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +17 more
  • Biopsy
  • +3 more
  • Augusta, Georgia
  • +4 more
Jan 25, 2023

Patients With Low Grade Ovarian or Peritoneal Tumors

Recruiting
  • Low Grade Ovarian Serous Adenocarcinoma
  • +5 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Jan 11, 2023